Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, First-in-human, Open-label, Dose Escalation Trial to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of BNT152+153 in Patients With Solid Tumors

NCT04710043 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT04710043
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04710043 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, First-in-human, Open-label, Dose Escalation Trial to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of BNT152+153 in Patients With Solid Tumors
Lead sponsor
BioNTech SE
Phase
Phase 1
Overall status
Completed
Start date
June 8, 2021
Completion date
September 10, 2025
Enrollment
86 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor